In Vitro Evaluation of 188Re-HEDP: A Mechanistic View of Bone Pain Palliations.

Skeletal metastasis is common in advanced stages of various cancers, particularly of the prostate and breast carcinoma. 188Re-HEDP (1-hydroxyethane 1, 1-diphosphonic acid) is a clinically established radiopharmaceutical for bone pain palliation of osseous metastasis, and it takes advantage of high bone affinity. The present work aims at elucidating the possible mechanisms of cell killing by 188Re-HEDP in osteosarcoma cells and biodistribution studies in mice.188Re-HEDP complex was prepared by using lyophilized HEDP kits prepared in-house. In vitro cellular uptake in mineralized bone matrix was found to be 13.41% ± 0.46% (at 2 hours), which was reduced to 2.44% ± 0.12% in the presence of excess amounts of unlabeled HEDP ligand. Uptake of 188Re-HEDP in bones of normal Swiss mice in vivo and mineralized bone in vitro indicated its affinity toward the bone matrix. The study also revealed that cellular toxicity and G2/M cell cycle arrest were dose dependent. At higher doses, G2/M cell cycle arrest was observed, which might be the major cause of cell death and a possible mechanism of bone pain relief.

[1]  M. Kameswaran,et al.  A Freeze-Dried Kit for the Preparation of (188)Re-HEDP for Bone Pain Palliation: Preparation and Preliminary Clinical Evaluation. , 2016, Cancer biotherapy & radiopharmaceuticals.

[2]  Sharmila Banerjee,et al.  Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons , 2016, Clinical & Experimental Metastasis.

[3]  Furn F. Knapp,et al.  An overview of radioisotope separation technologies for development of 188W/188Re radionuclide generators providing 188Re to meet future research and clinical demands , 2015 .

[4]  P. Hou,et al.  Iodine-131 induces apoptosis in HTori-3 human thyrocyte cell line and G2/M phase arrest in a p53-independent pathway. , 2015, Molecular medicine reports.

[5]  F. Estévez,et al.  Induction of G2/M phase arrest and apoptosis by the flavonoid tamarixetin on human leukemia cells , 2014, Molecular carcinogenesis.

[6]  KumarChandan,et al.  Camptothecin Enhances Cell Death Induced by 177Lu-EDTMP in Osteosarcoma Cells , 2014 .

[7]  G. Samuel,et al.  Cellular toxicity and apoptosis studies in osteocarcinoma cells, a comparison of 177Lu-EDTMP and Lu-EDTMP. , 2013, Current radiopharmaceuticals.

[8]  M. Andreou,et al.  Rhenium-188 Production in Hospitals, by W-188/Re-188 Generator, for Easy Use in Radionuclide Therapy , 2013, International journal of molecular imaging.

[9]  M. Harrison,et al.  Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease , 2013, Cancer management and research.

[10]  K. Ogawa,et al.  Bone target radiotracers for palliative therapy of bone metastases. , 2012, Current medicinal chemistry.

[11]  Jing Wang,et al.  In Vitro Study on Apoptosis Induced by Strontium-89 in Human Breast Carcinoma Cell Line , 2011, Journal of biomedicine & biotechnology.

[12]  Yu-Chi Chen,et al.  Breast cancer metastasis to the bone: mechanisms of bone loss , 2010, Breast Cancer Research.

[13]  A. Serafini,et al.  Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. , 2010, Seminars in nuclear medicine.

[14]  Janet E. Hall,et al.  Control of the G2/M checkpoints after exposure to low doses of ionising radiation: implications for hyper-radiosensitivity. , 2010, DNA repair.

[15]  K. Riklund,et al.  Iodine-131 induces mitotic catastrophes and activates apoptotic pathways in HeLa Hep2 cells. , 2008, Cancer biotherapy & radiopharmaceuticals.

[16]  M. Mitterhauser,et al.  What to consider in the development of new bone seekers: mechanistic and tracer-related aspects. , 2008, Nuclear medicine and biology.

[17]  P P van Rijk,et al.  Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases. , 2007, Anti-cancer agents in medicinal chemistry.

[18]  R. C. Vignesh,et al.  Effect of ethanol on human osteosarcoma cell proliferation, differentiation and mineralization. , 2006, Toxicology.

[19]  C. Divgi,et al.  Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  D. Prockop,et al.  An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. , 2004, Analytical biochemistry.

[21]  W. Wadsak,et al.  Binding studies of [(18)F]-fluoride and polyphosphonates radiolabelled with [(111)In], [(99m)Tc], [(153)Sm], and [(188)Re] on bone compartments: a new model for the pre vivo evaluation of bone seekers? , 2004, Bone.

[22]  M. Lam,et al.  186Re-HEDP for metastatic bone pain in breast cancer patients , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  V. Budach,et al.  Increased radiation-induced apoptosis and altered cell cycle progression of human lung cancer cell lines by antisense oligodeoxynucleotides targeting p53 and p21WAF1/CIP1 , 2003, Cancer Gene Therapy.

[24]  R. Autorino,et al.  External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life. , 2003, Oncology reports.

[25]  J. Vučina.  [Technetium-99m production for use in nuclear medicine]. , 2000, Medicinski pregled.

[26]  H. Biersack,et al.  Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases , 2000, European Journal of Nuclear Medicine.

[27]  V. Cocquyt,et al.  Pharmacokinetics of Intrvenous Alendronate , 1999 .

[28]  J. Asplin,et al.  Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. , 1999, Kidney international.

[29]  Jie Yuan,et al.  Studies of the Structure and Composition of Rhenium−1,1-Hydroxyethylidenediphosphonate (HEDP) Analogues of the Radiotherapeutic Agent 186ReHEDP , 1997 .

[30]  D. Kohavi,et al.  Uptake and biodistribution of 99mtechnetium methylene-[32P] diphosphonate during endosteal healing around titanium, stainless steel and hydroxyapatite implants in rat tibial bone. , 1995, Biomaterials.

[31]  Z. Schwartz,et al.  Uptake and biodistribution of technetium-99m-MD32P during rat tibial bone repair. , 1993, Journal of Nuclear Medicine.

[32]  R. Robinson.  "Systemic radioisotopic therapy of primary and metastatic bone cancer". , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  F. Knapp,et al.  Radionuclide Generators: New Systems for Nuclear Medicine Applications , 1984 .

[34]  E. Kim,et al.  99mTc-hydroxymethane diphosphonate: a new bone imaging agent with a low tin content. , 1980, Radiology.

[35]  F D Thomas,et al.  Technetium-99m-methylene diphosphonate--a superior agent for skeletal imaging: comparison with other technetium complexes. , 1975, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  R. Callahan,et al.  New bone scanning agent: 99m Tc-labeled 1-hydroxy-ethylidene-1, 1-disodium phosphonate. , 1972, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.